ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 20.6
(-4.63%)
SEK 20.6
(-4.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -102.45 Million SEK | 21.39% |
| 2022 | -124.49 Million SEK | -172.37% |
| 2021 | -46.37 Million SEK | -60.53% |
| 2020 | -28.47 Million SEK | -86.83% |
| 2019 | -15.24 Million SEK | 2.44% |
| 2018 | -14.29 Million SEK | -73.41% |
| 2017 | -8.49 Million SEK | -22.29% |
| 2016 | -7.36 Million SEK | -24.62% |
| 2015 | -5.91 Million SEK | -0.25% |
| 2014 | -5.89 Million SEK | -1.49% |
| 2013 | -5.8 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -13.29 Million SEK | 29.29% |
| 2024 Q2 | -21.61 Million SEK | -50.09% |
| 2023 Q2 | -32.8 Million SEK | -10.66% |
| 2023 Q4 | -14.2 Million SEK | 34.62% |
| 2023 FY | - SEK | 21.39% |
| 2023 Q3 | -21.73 Million SEK | 33.75% |
| 2023 Q1 | -29.64 Million SEK | 44.0% |
| 2022 Q3 | -31.13 Million SEK | -19.29% |
| 2022 FY | - SEK | -172.37% |
| 2022 Q4 | -52.93 Million SEK | -70.01% |
| 2022 Q2 | -26.09 Million SEK | -82.14% |
| 2022 Q1 | -14.32 Million SEK | 8.5% |
| 2021 Q3 | -9.5 Million SEK | 0.04% |
| 2021 Q1 | -10.99 Million SEK | 33.11% |
| 2021 Q2 | -9.51 Million SEK | 13.5% |
| 2021 FY | - SEK | -60.53% |
| 2021 Q4 | -15.66 Million SEK | -64.72% |
| 2020 Q2 | -3.96 Million SEK | 9.51% |
| 2020 Q1 | -4.38 Million SEK | 37.52% |
| 2020 Q3 | -3.33 Million SEK | 15.9% |
| 2020 FY | - SEK | -86.83% |
| 2020 Q4 | -16.44 Million SEK | -392.51% |
| 2019 Q4 | -7.02 Million SEK | -200.0% |
| 2019 Q1 | -3.84 Million SEK | 38.38% |
| 2019 FY | - SEK | 2.44% |
| 2019 Q3 | -2.34 Million SEK | -14.82% |
| 2019 Q2 | -2.03 Million SEK | 46.98% |
| 2018 Q1 | -2.73 Million SEK | 21.06% |
| 2018 FY | - SEK | -73.41% |
| 2018 Q3 | -3.12 Million SEK | 7.29% |
| 2018 Q2 | -3.37 Million SEK | -23.45% |
| 2018 Q4 | -6.23 Million SEK | -99.42% |
| 2017 Q1 | -538 Thousand SEK | 86.1% |
| 2017 Q3 | -2.59 Million SEK | -7.28% |
| 2017 Q4 | -3.46 Million SEK | -33.56% |
| 2017 FY | - SEK | -22.29% |
| 2017 Q2 | -2.41 Million SEK | -349.07% |
| 2016 Q4 | -3.87 Million SEK | -84.55% |
| 2016 Q2 | -1.54 Million SEK | 78.53% |
| 2016 FY | - SEK | -24.62% |
| 2016 Q1 | -7.2 Million SEK | 0.0% |
| 2016 Q3 | -2.09 Million SEK | -35.64% |
| 2015 FY | - SEK | -0.25% |
| 2014 FY | - SEK | -1.49% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 56.883% |
| Ziccum AB (publ) | -20.34 Million SEK | -403.653% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 5122750.0% |
| BioArctic AB (publ) | 275.38 Million SEK | 137.203% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -4825.625% |
| Mendus AB (publ) | -97.84 Million SEK | -4.708% |
| Genovis AB (publ.) | 64.57 Million SEK | 258.665% |
| Intervacc AB (publ) | -68.98 Million SEK | -48.526% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -662.81% |
| Active Biotech AB (publ) | -43.88 Million SEK | -133.447% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 426.242% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -86.938% |
| Aptahem AB (publ) | -10 Million SEK | -923.586% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 67.728% |
| Kancera AB (publ) | -61.88 Million SEK | -65.543% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 987.116% |
| Fluicell AB (publ) | -25.91 Million SEK | -295.358% |
| Saniona AB (publ) | -69.69 Million SEK | -47.002% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -746.439% |
| Biovica International AB (publ) | -119.5 Million SEK | 14.27% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -142.642% |
| AcouSort AB (publ) | -16.7 Million SEK | -513.381% |
| Xintela AB (publ) | -53.47 Million SEK | -91.605% |
| Abliva AB (publ) | -93.6 Million SEK | -9.449% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 67.893% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -282.53% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1510.033% |
| Amniotics AB (publ) | -27.14 Million SEK | -277.456% |
| 2cureX AB (publ) | -35.13 Million SEK | -191.59% |
| CombiGene AB (publ) | -35.33 Million SEK | -189.939% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -620.637% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 72.145% |
| Camurus AB (publ) | 562.54 Million SEK | 118.212% |
| Corline Biomedical AB | -1.69 Million SEK | -5958.723% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 40.889% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -176.721% |
| I-Tech AB | 30.34 Million SEK | 437.627% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 85.662% |
| Cyxone AB (publ) | -20.41 Million SEK | -401.876% |
| Biosergen AB | 228 Thousand SEK | 45035.526% |
| Cantargia AB (publ) | -284.31 Million SEK | 63.965% |
| NextCell Pharma AB | -40.98 Million SEK | -149.976% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 39.668% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -499.684% |
| Nanologica AB (publ) | -62.11 Million SEK | -64.93% |
| SynAct Pharma AB | -222.7 Million SEK | 53.995% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -133.586% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 33212.054% |
| LIDDS AB (publ) | -39.67 Million SEK | -158.263% |
| Lipum AB (publ) | -37.11 Million SEK | -176.012% |
| BioInvent International AB (publ) | -312.7 Million SEK | 67.237% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 244041.522% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 55.767% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1062.59% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 10.838% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -423.28% |
| Simris Alg AB (publ) | -22.36 Million SEK | -358.136% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 27.261% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 63.673% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 5.624% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -793.304% |